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Developmental Toxicity of Four Glycol Ethers
Applied Cutaneously to Rats
by Bryan D. Hardin,* Phillip T. Goadt and JeAnne R. Burg*
Previous NIOSH studies demonstrated the embryo- and fetotoxicity and teratogenicity ofethylene glycol
monoethyl ether (EGEE) applied to the shaved skin of pregnant rats. In the present study ethylene glycol
monoethyl ether acetate (EGEEA), ethylene glycol monobutyl ether (EGBE), and diethylene glycol
monoethyl ether (diEGEE) were tested in the same experimental model, using distilled water as the
negative control and EGEE as a positive control. Water or undiluted glycols were applied four times daily
on days 7 to 16 ofgestation to the shaved interscapular skin with an automatic pipetter. Volumes ofEGEE
(0.25 mL), EGEEA (0.35 mL), and diEGEE (0.35 mL) were approximately equimolar (2.6 mmole per
treatment). EGBE at 0.35 mL four times daily (approximately 2.7 mmole per treatment) killed 10 of 11
treated rats, and was subsequently tested at 0.12 mL (0.9 mmole) per treatment. EGEE- and EGEEA-
treated rats showed a reduction in body weight relative to water controls that was associated with
completely resorbed litters and significantly fewer live fetuses per litter. Fetal body weights were also
significantly reduced in those groups. Visceral malformations and skeletal variations were significantly
increased in EGEE and EGEEA groups over the negative control group. No embryotoxic, fetotoxic, or
teratogenic effects were detected in the EGBE- or diEGEE-treated litters.
Introduction
The alkyl ether derivatives ofethylene and diethylene
gylcol are an important class ofsolvents with numerous
applications in consumer products as well as in indus-
trial processes. Several members ofthis chemical family
have recently been shown to be potent reproductive
toxins in several animal species, as reviewed in detail
elsewhere (1,2). Teratogenicity has been reported for
ethylene glycol monomethyl ether (EGME) in mice
(3) and rats (4); for ethylene glycol dimethyl ether
(EGdiME) in mice (5); for ethylene glycol monoethyl
ether (EGEE) in rabbits (6) and rats (6-8); and for
ethylene glycol monoethyl ether acetate (EGEEA) in
rats (4). Evidence of testicular toxicity has been re-
ported for EGME in mice (9-11), rats (10-12), and
rabbits (12); for ethylene glycol monomethyl ether
acetate (EGMEA) in mice (9); for EGEE in mice (9),
rats (8), and dogs (8); for EGEEA in mice (9); and for
diethylene glycol dimethyl ether (diEGdiME) in mice
and rats (13). In contrast, ethylene glycol monobutyl
ether (EGBE) and diethylene glycol monoethyl ether
(diEGEE) both have been tested once by inhalation
exposure for teratogenicity (4) with negative results.
EGBE and ethylene glycol monophenyl ether (EGPhE)
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have been tested for testicular toxicity with negative
results (9).
The glycol ethers do not have especially high vapor
pressures (14), but they penetrate the skin readily and
are commonly used in applications that are conducive to
skin contact. Hardin et al. (7) applied undiluted EGEE
to the skin of pregnant rats to investigate its potential
for developmental toxicity by this route of exposure.
When 0.5 mL was applied four times daily on days 7 to
16 of gestation, all pregnant females had completely
resorbed litters. Treatment with 0.25 mL on the same
schedule induced significant embryotoxic, fetotoxic, and
teratogenic effects (7). The cardiovascular system was
the primary target for visceral malformations, as had
been previously reported in rats (4,6) and rabbits (6)
exposed to EGEE by inhalation. The present study was
conducted to evaluate thereproductive and developmen-
taltoxicity ofthree other alkyl glycol ethers in the same
2utaneous exposure model.
Methods and Materials
Purified glycol ethers were purchased from Fisher
Scientific: EGEE, Catalog No. E-180, Lot 70107;
EGEEA, Catalog No. E-181, Lot 794501; EGBE,
Catalog No. E-179, Lot 703549; and diEGEE, Catalog
No. D-51, Lot 792796. Time-mated primigravida SPF
Sprague-Dawley rats were purchased from Charles
River Breeding Laboratories, Wilmington, MA. Rats
were shipped on day 4 and received on day 5 ofgestationHARDIN, GOAD AND BURG
(sperm = day 1), when they were weighed and marked
for individual identification by toe clipping. The inter-
scapular region was shaved with electric clippers on day
5 or 6, and rats were formally randomized by weight to
one offive groups. All rats were singly housed through-
out the study in suspended stainless steel cages in a
ventilated cage rack (Hazelton Systems, Aberdeen,
MD) with free access to food and water. These cages are
designed such that room air was drawn through the
wire mesh floors of each cage and into an overhead
plenum from which the exhaust air was ducted directly
to a fume hood. Light was on a 12-hr light-dark cycle.
Rats were received in two separate shipments in
consecutive weeks and the experiment was conducted in
two replicates. Tieatment volumes were selected based
on results of the earlier study of the teratogenicity of
EGEE when applied to the skin ofrats (7). A volume of
EGEE (0.25 mL four times daily) that was teratogenic
in that study was used as the positive control. Approxi-
mately equimolar volumes (0.35 mL fourtimes daily, for
a total daily dose of 1.4 mL) of EGEEA, EGBE, and
diEGEE were employed initially. Because the rats
treated with 0.35 mL of EGBE showed marked toxic
effects, the treatment volume was reduced in the
second replicate to 0.12 mL EGBE four times daily.
Undiluted glycols or water (control) were applied to the
shaved interscapular region using an automatic pipetter
(Finpipette) four times daily at 2.5-hr intervals on days
7 to 16 of gestation.
In addition to the randomization body weights (day 5
of gestation), body weights were recorded on the first
and sixth days of treatment and on the first and fifth
post-treatment days (gestation days 7, 12, 17 and 21,
respectively). On day 21, females were killed by CO2
asphyxiation and gravid uterus weights were recorded.
Fetuses were weighed and examined for external
malformations. Alternate fetuses were preserved in
Bouin's fluid or 70% ethanol for subsequent visceral
examination by the Wilson (15) method or skeletal
examination according to Staples and Schnell (16).
Uterifrom apparently nonpregnant females were placed
in 10% sodium sulfide to reveal early termination of
pregnancy
All maternal and fetal body weights, maternal organ
weights were analyzed by analysis of variance tech-
niques. If significant (p < 0.05) differences between
groups were detected, a posteriori Waller-Duncan
K-ratio t-tests were conducted to describe in more
detail the source of variation. Implantation data (total
and numbers of live and dead) were analyzed using the
Kruskal-Wallis test. Frequencies of malformations and
of variations were analyzed by Fisher-Irwin exact test
of the numbers of affected litters. Because repeated
contrasts were made with the water control group, the
level ofsignificance was set at p < 0.01. All procedures
were carried out using SAS 82.3 and BMDP statistical
packages on the Parklawn Computer Center, Rock-
ville, MD.
Results
Toxic signs were not noted in EGEE-, EGEEA-, or
diEGEE-treated rats. However, red-stained urine was
observed after only two treatments with 0.35 mL
EGBE. By the end of the first treatment day, EGBE-
treated rats produced burgundy-colored urine. Contin-
ued treatment with EGBE led to ataxia progressing to
moderate to marked inactivity and rough haircoats with
dark stains around the muzzle and ano-genital area.
Several rats' tails blackened distally and were gradually
eaten away as the apparent necrosis progressed. Deaths
occurred on the third to seventh days oftreatment (days
Table 1. Gestational body weights (mean ± SD) of pregnant rats in various treatment groups.
Treatment group
EGEE EGEEA EGBEa diEGEE Water
(0.25 mL) (0.35 mL) (0.12 mL) (0.35 mL) (control)
Group size 18 18 9 13 17
Body weight, g
Day 5 188 ± 8 192 ± 9 192 ± 10 193 ± 7 189 ± 7
Day 7 210 ± 7 212 ± 12 219 ± 12 213 ± 10 210 ± 7
Day 12 239 ± 10 240 ± 14 239 ± 13 242 ± 12 246 ± 11
Day 17 262 ± 15 256 ± 17 268 ± 16 269 ± 17 278 ± 14
Day 21 284 ± 32 268 ± 29 336 ± 30 323 ± 31 331 ± 22
Body weight gain, g
Day 5-7 22 ± 8 20 ± 7 27 ± 6 19 ± 8 21 ± 5
Day 5-12* 51 ± 9xy 48 ± 9Y 48 ± 12Y 49 ± 7x,y 57 ± lOx
Day 5-17t 74 ± 13Y 65 ± 12z 77 ± 18Y 76 ± 13Y 89 ± 11x
Day 5-21t 97 ± 29Y 76 ± 27Z 144 ± 31x 130 ± 27x 142 ± 19x
Gravid uterus weight, gt 23 ± 21Y 9 ± 12z 59 ± 22X 65 ± 20X 60 ± 15x
Extragestational body weight, gb 261 ± 18 259 ± 24 276 ± 18 258 ± 18 271 ± 15
Extragestational body weight gain, g* 74 ± 15x y 67 ± 20v 85 ± 18X 65 + 16Y 82 ± 15x
aReplicate 2 only. All other groups are combined data for replicates 1 and 2.
bDay 21 body weight minus gravid uterus weight.
cExtragestational body weight minus day 5 body weight.
*Significant difference (p < 0.05). Groups with the same superscript do not differ from each other by a posteriori test.
tSignificant difference (p < 0.001). Groups with the same superscript do not differ from each other by a posteriori test.
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9-13 of gestation). In replicate 1, only one of 11 rats
treated with 0.35 mL EGBE survived. In the second
replicate, the EGBE treatment volume was reduced to
0.12 mL four times daily (0.48 mL EGBE/day) and no
toxic signs were noted.
Body weights ofpregnant females are summarized in
Table 1, along with gravid uterus and extragestational
body weight (day 21 body weight minus gravid uterus
weight). Day 5 (randomization) body weights did not
differ between replicates and body weight data were
therefore combined across replicates foranalysis. Analy-
sis ofvariance confirmed that body weights on day 5 did
not differ across treatment groups. Body weights on
days 7, 12, 17, and 21 were analyzed by multivariate
analysis ofthe change relative to day 5. Treatment with
EGEE and EGEEA profoundly reduced maternal body
weight gain, and at days 17 and 21 body weight gain in
the EGEEA group was significantly lower than in the
EGEE positive controls. Gravid uterus weights were
also markedly reduced in those groups, accounting for
much ofthe difference in body weight. Extragestational
body weights did not differ significantly (p < 0.10),
but extragestational body weight gain was significantly
different across groups (p < 0.05). Extragestational
weight gain in EGEEA and diEGEE groups was
significantly less than in the water controls by a
posteriori test.
Data in Table 2 reveal that, relative to the water
controls, both EGEE and EGEEA treatments were
strongly embryotoxic as reflected in significantly higher
frequencies ofcompletely resorbed litters and increased
numbers of dead implants per litter. The number of
dead implants per litter was also significantly higher in
EGEEA- than in the positive control EGEE-treated
litters. Considering only litters with at least one live
fetus, there was a significant reduction in the number of
live fetuses per litter in the EGEE- and EGEEA-
treated groups. Similarly, the body weights of live
fetuses in these two groups were significantly reduced
relative to the water-treated controls. No evidence of
embryo- or fetotoxicity was noted in the EGBE and
diEGEE groups. On gross examination of fetuses, the
only malformations noted were three fetuses from
EGEE-treated litters with acaudia and imperforate
anus (Table 2).
Discussion
The results of this study confirmed the previously
reported embryo- and fetotoxicity and teratogenicity of
EGEE applied to the skin of pregnant rats. As was
previously reported, cardiovascular defects were the
predominant visceral malformation. A wide spectrum of
skeletal variants was also seen both in the present and
the earlier skin teratology evaluation of EGEE. Verte-
bral malformations and reduced skeletal ossification
also occurred with increased frequency in EGEE-
treated litters but were not statistically significant. The
only gross malformations noted in the study were three
EGEE-treated fetuses with acaudia and imperforate
anus, a defect also seen in the previous evaluation of
cutaneously applied EGEE.
The spectrum and frequency of malformations and
variations in the EGEEA-treated litters was remarka-
bly similar to that described for the EGEE-treated
group. Statistically significant increases in cardiovascu-
larmalformations and skeletal variations were detected.
Similar responses to EGEE and EGEEA are not
unexpected since EGEEA should be rapidly hydrolyzed
in vivo to EGEE and acetate. At an equimolar dose, in
fact, EGEEA in this study caused even more severe
maternal, embryo, and fetal toxicity than did EGEE.
This was reflected in significantly reduced in body
weight gain (Table 1) and increased dead implants per
litter (Table 2) in EGEEA-treated litters relative to the
EGEE litters.
Neither EGBE nor diEGEE was associated with
embryo- or fetotoxicity, and the incidence of visceral
and skeletal defects was not increased in either group.
Table 2. Observations at necropsy.
TIeatment group
EGEE EGEEA EGBEa diEGEE Water
(0.25 mL) (0.35 mL) (0.12 mL) (0.35 mL) (control)
Group size 18 18 9 13 17
No. (%) litters totally resorbed 7*(38.9) 13*(72.2) 0 0 0
No. implants per litterb 11.6 ± 2.9 11.7 ± 2.7 11.2 ± 4.3 11.8 ± 1.7 11.6 ± 2.5
No. dead implants per litter"t 7.7 ± 5.1y 10.6 ± 3.3x 1.2 ± 1.0Z 1.2 ± 1.2z 1.2 ± 1.2z
No. live fetuses per litter with
live fetuses"t 6.5 ± 4.1y 4.2 ± 3.4Y 10.0 ± 3.8x 10.6 ± 2.3x 10.4 ± 2.6X
(no. litters) (11) (5) (9) (13) (17)
Fetal body weight, gbt 3.0 ± 0.6y 2.6 ± 1.0v 4.2 ± 0.7x 3.9 ± 0.8x 3.9 ± 0.6x
Gross malformations
litters (fetuses) 3(3)C 0 0 0 0
aReplicate 2 only. All other groups are combined data for replicates 1 and 2.
bMean ± SD.
cAcaudia and imperforate anus.
*Differs significantly (p < 0.01) from water controls.
tSignificant differences (p < 0.001). Groups with the same superscript do not differ from each other (p > 0.05) by a posteriori test.
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EGBE is a potent hemolytic agent in rodents, as
reflected in the rapid onset ofred-stained urine (within
5 hr of first dosing) and subsequent death of rats
receiving 0.35-mL doses. Equimolar volumes ofEGEE,
EGEEA and diEGEE caused no mortality and no
clinical signs of toxicity. The extragestational body
weight gain (Table 1) of diEGEE-treated rats was
significantly reduced, to a degree comparable to the
reductiontheEGEEA-treated rats. Thus, whilediEGEE
was not embryo- or fetotoxic, it was maternally toxic
under these test conditions.
In summary, the results of this study confirm that
EGEE can be absorbed in embryotoxic, fetotoxic, and
teratogenic quantities through the intact skin of preg-
nant rats. EGEEA was shown to share these properties
and to be at least as active as EGEE by this route. It
has been previously reported that inhalation exposure
ofpregnant rats to EGBE resulted in no developmental
toxicity, and none was detected here at approximately
one-third the molar dose used for EGEE and EGEEA.
A treatment volume of EGBE equimolar to the EGEE
and EGEEA volume was strongly hemolytic and ulti-
mately lethal, demonstrating that EGBE also pene-
trates the skin readily. There also was no measurable
developmental toxicity in rats treated with diEGEE,
despite administration at a dose causingslight maternal
toxicity. These data demonstrate that reproductive and
developmental toxicity, like other manifestations of
glycol ether toxicity, are possible following cutaneous
exposure.
Table 3. Visceral malformations and variations: number of litters (fetuses) affected.
Treatment Group
EGEE EGEEA EGBEa diEGEE Water
(0.25 mL) (0.35 mL) (0.12 mL) (0.35 mL) (control)
Tbtal examined 10(34) 3(10) 8(45) 13(70) 17(87)
Malformations
Cardiovascular: total 8(9)t 3(5)t 0 0 0
Right aorta 4(4)b 2(2) 0 0 0
Double aorta 1(1) 1(1) 0 0 0
Right ductus 3(3)b 1(1) 0 0 0
Ventricular septal defect 5(5) 3(5) 0 0 0
Abnormal subelavian 1(1) 0 0 0 0
Renal: total 7(8)* 1(2) 0 2(3) 3(3)
Hydronephrosis 4(4) 1(1) 0 1(2) 0
Hydroureter 4(4) 0 0 1(2) 3(3)
Ectopic kidney 1(2) 1(1) 0 1(1) 0
Hypoplastic kidney 0 1(1) 0 0 0
Fused kidneys 1(1) 0 0 0 0
Brain: total 4(4)* 1(2) 0 2(3) 0
Hydrocephalus 2(2) 1(2) 0 2(3) 0
Hemorrhage 2(2) 0 0 0 0
Eye: total 2(2) 2(2) 0 0 0
Microophthalmia 1(1) 0 0 0 0
Abnormal optic nerve 1(1) 0 0 0 0
Folded retina 2(2) 2(2) 0 0 0
Tobtal malformations 10(21)t 3(8) 0(0) 3(5) 3(3)
Variations
Cardiovascular
Missing innominate 2(2) 1(1) 0 0 0
Renal: total 5(7) 0 4(5) 6(13) 10(15)
Dilated renal pelvis 2(3) 0 0 3(6) 6(7)
Dilated ureter 4(5) 0 4(5) 4(9) 7(10)
Tbtal variations 5(8) 1(1) 4(5) 6(13) 10(15)
Testicular defects
Males examined 21 6 23 40 39
Testicular: total 3(3) 1(1) 1(1) 4(4) 1(1)
Ectopic (slight) 2(2) 1(1) 1(1) 4(4) 1(1)
Undescended 1(1) 0 0 0 0
Agenesis 1(1) 0 0 0 0
aReplicate 2 only. All other groups are combined data for replicates 1 and 2.
bIncludes one fetus with situs inversus.
*Differs significantly from water controls (p < 0.01) by two-tail Fisher-Irwin exact test of litters affected.
tDiffers significantly from water controls (p < 0.001) by two-tail Fisher-Irwin test of litters affected.
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Table 4. Skeletal malformations and variations: number of litters (fetuses) affected.
Treatment group
EGEE EGEEA EGBEa diEGEE Water
(0.25 mL) (0.35 mL) (0.12 mL) (0.35 mL) (control)
Tbtal examined 11(36) 5(11) 9(45) 13(67) 17(90)
Malformations
Ribs: total 2(2) 2(2) 1(1) 2(4) 1(1)
Missing ribs 2(2)b 0 0 2(3) 1(1)
Fused, malformed 1(1)b 2(2) 0 1(2) 0
Cervical 0 0 1(1) 0 0
Vertebrae: total 4(5) 0 0 2(4) 0
Fused arches 2(2)b 0 0 1(1) 0
Extra lumbar 2(2) 0 0 1(3) 0
Reduced lumbar 2(3)b 0 0 0 0
Reduced thoracic 1(1)b 0 0 1(1) 0
Absent arch 0 0 0 1(1) 0
Scoliosis 0 1(1) 0 0 0
Missing tympanic ring 0 0 0 1(1) 0
Total malformations 4(5) 2(2) 1(1) 3(5) 1(1)
Variations
Ribs: total 6(13)* 5(6). 3(4) 5(12) 1(1)
Extra thoracic 2(6) 0 0 0 0
Extra lumbar 5(7)b 5(6) 3(4) 5(12) 1(1)
Vertebrae: total 10(32)t 5(11) 1(1) 3(6) 0
Reduced sacral (< 6) 2(2)b 0 0 0 0
Missing lumbo-sacral arch 2(2) 1(1) 1(1) 0 0
Increased thoracic 1(3) 0 0 0 0
Centra: misshaped 7(16)b 5(10) 0 2(3) 0
Centra: absent, incomplete 7(23) 5(11) 0 2(5) 0
Sternebrae: total 11(32) 4(9) 6(13) 7(18) 13(28)
Misaligned 6(8) 0 0 1(3) 2(2)
Split 0 1(1) 0 0 0
Decreased number (< 6) 9(29) 4(9) 6(13) 7(17) 13(27)
Reduced ossification: total 5(14) 5(11) 3(3) 3(3) 1(1)
Skull 2(8) 5(11) 3(3) 2(2) 0
Pelvic girdle 4(8)b 4(6) 0 0 0
Decreased metatarsals (< 4) 2(3)b 4(7) 0 1(1) 0
Decreased metacarpals (< 3) 2(5) 2(5) 1(1) 0 1(1)
Tbtal variations 11(34) 5(11) 7(16) 9(22) 13(29)
aReplicate 2 only. All other groups are combined data for replicates 1 and 2.
bIndicates two fetuses with acaudia and imperforate anus.
*Differs significantly from water controls (p < 0.01) by two-tail Fisher-Irwin exact test of litters affected.
tDiffers significantly from water controls (p < 0.001) by two-tail Fisher-Irwin exact test of litters affected.
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